Cardiol Therapeutics/$CRDL
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Cardiol Therapeutics
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.
Ticker
$CRDL
Sector
Primary listing
Employees
18
Headquarters
Oakville, Canada
Website
CRDL Metrics
BasicAdvanced
$98M
-
-$0.34
0.79
-
Price and volume
Market cap
$98M
Beta
0.79
52-week high
$2.37
52-week low
$0.77
Average daily volume
1.1M
Financial strength
Current ratio
2.465
Quick ratio
2.303
Long term debt to equity
0.906
Total debt to equity
1.207
Profitability
EBITDA (TTM)
-29.056
Management effectiveness
Return on assets (TTM)
-108.74%
Return on equity (TTM)
-276.41%
Valuation
Price to book
11.34
Price to tangible book (TTM)
11.34
Price to free cash flow (TTM)
-5.084
Free cash flow yield (TTM)
-19.67%
Free cash flow per share (TTM)
-0.23
Growth
Earnings per share change (TTM)
7.76%
3-year earnings per share growth (CAGR)
-5.80%
What the Analysts think about CRDL
Analyst ratings (Buy, Hold, Sell) for Cardiol Therapeutics stock.
CRDL Financial Performance
Revenues and expenses
CRDL Earnings Performance
Company profitability
CRDL News
AllArticlesVideos
Cardiol Therapeutics to Participate in Fireside Chat at Canaccord Genuity's 45th Annual Growth Conference
Newsfile Corp·2 weeks ago
Cardiol Therapeutics Announces Topline Results from the Phase II ARCHER Trial of CardiolRx(TM) in Acute Myocarditis
Newsfile Corp·3 weeks ago
Cardiol Therapeutics Announces Database Lock for Phase II ARCHER Trial of CardiolRx(TM) in Acute Myocarditis
Newsfile Corp·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Cardiol Therapeutics stock?
Cardiol Therapeutics (CRDL) has a market cap of $98M as of August 25, 2025.
What is the P/E ratio for Cardiol Therapeutics stock?
The price to earnings (P/E) ratio for Cardiol Therapeutics (CRDL) stock is 0 as of August 25, 2025.
Does Cardiol Therapeutics stock pay dividends?
No, Cardiol Therapeutics (CRDL) stock does not pay dividends to its shareholders as of August 25, 2025.
When is the next Cardiol Therapeutics dividend payment date?
Cardiol Therapeutics (CRDL) stock does not pay dividends to its shareholders.
What is the beta indicator for Cardiol Therapeutics?
Cardiol Therapeutics (CRDL) has a beta rating of 0.79. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.